Health technology assessment : HTA
-
Health Technol Assess · Sep 2018
Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
Neuroendocrine tumours (NETs) are a group of heterogeneous cancers that develop in cells in the diffuse neuroendocrine system. ⋯ The National Institute for Health Research Health Technology Assessment programme.